Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. September 2017 08:00 ET | Quelle: Zai Lab Limited

Zai Lab Limited Announces Dosing of First Patient in Phase 3 Registration Trial of ZL-2306 (niraparib) for Treatment of Ovarian Cancer

SHANGHAI, China, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, announced today that it has dosed the first patient in a...
22. September 2017 16:05 ET | Quelle: Zai Lab Limited

Zai Lab Limited Announces Closing of U.S. Initial Public Offering of ADSs

NEW YORK, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) announces the closing of its U.S. initial public offering of 9,583,333 American depositary shares (“ADSs”) at a price of...
20. September 2017 09:52 ET | Quelle: Zai Lab Limited

Zai Lab Limited Announces Pricing of U.S. Initial Public Offering of ADSs

NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) announces the pricing of its U.S. initial public offering of American depositary shares (“ADSs”) (the “IPO”), raising gross...
19. September 2017 18:56 ET | Quelle: Zai Lab Limited

Zai Lab Limited Announces Upsizing of U.S. Initial Public Offering of ADSs

NEW YORK, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) announces its intent to upsize its U.S. initial public offering of American depositary shares (“ADSs”). Zai Lab now plans to...